First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

Research To Practice | Oncology Videos · Apr 10, 2025 · 57m

Featuring an interview with Dr Justin F Gainor, including the following topics:

Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00)

Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38)

Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32)

Tolerability profile of lorlatinib (23:28)

Review of clinical investigator survey results (37:08)

Novel ALK inhibitors under clinical development (53:22)

CME information…